Frits Van Rhee
Concepts (589)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 167 | 2026 | 3082 | 11.470 |
Why?
| | Antibodies, Monoclonal | 26 | 2024 | 477 | 5.870 |
Why?
| | Hematopoietic Stem Cell Transplantation | 29 | 2026 | 610 | 3.170 |
Why?
| | Antineoplastic Agents | 18 | 2024 | 1232 | 3.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 42 | 2024 | 1043 | 3.050 |
Why?
| | Humans | 223 | 2026 | 53230 | 2.210 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 11 | 2025 | 123 | 1.940 |
Why?
| | Thalidomide | 24 | 2024 | 378 | 1.880 |
Why?
| | Neoplasm Recurrence, Local | 15 | 2024 | 647 | 1.690 |
Why?
| | Transplantation, Autologous | 27 | 2026 | 488 | 1.670 |
Why?
| | Immunotherapy, Adoptive | 9 | 2024 | 163 | 1.640 |
Why?
| | Killer Cells, Natural | 8 | 2024 | 113 | 1.610 |
Why?
| | Middle Aged | 83 | 2026 | 13419 | 1.580 |
Why?
| | Gene Expression Profiling | 28 | 2025 | 1112 | 1.570 |
Why?
| | Interleukin-6 | 12 | 2023 | 272 | 1.540 |
Why?
| | Hematologic Neoplasms | 3 | 2022 | 101 | 1.480 |
Why?
| | Neoplasm Proteins | 13 | 2022 | 330 | 1.480 |
Why?
| | Aged | 83 | 2026 | 10429 | 1.440 |
Why?
| | Prognosis | 48 | 2025 | 2118 | 1.440 |
Why?
| | Antigens, Neoplasm | 6 | 2014 | 146 | 1.330 |
Why?
| | Clinical Trials as Topic | 13 | 2022 | 466 | 1.320 |
Why?
| | Antibodies, Bispecific | 7 | 2025 | 108 | 1.300 |
Why?
| | Stem Cell Transplantation | 10 | 2022 | 191 | 1.250 |
Why?
| | Adult | 63 | 2026 | 14534 | 1.240 |
Why?
| | B-Cell Maturation Antigen | 9 | 2025 | 101 | 1.230 |
Why?
| | Male | 93 | 2026 | 27435 | 1.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 20 | 2022 | 868 | 1.180 |
Why?
| | Female | 95 | 2026 | 28782 | 1.170 |
Why?
| | Combined Modality Therapy | 19 | 2024 | 640 | 1.160 |
Why?
| | Chromosomes, Human, Pair 1 | 9 | 2023 | 95 | 1.150 |
Why?
| | Herpesvirus 8, Human | 7 | 2021 | 98 | 1.120 |
Why?
| | Translocation, Genetic | 10 | 2022 | 266 | 1.090 |
Why?
| | Treatment Outcome | 47 | 2024 | 5595 | 1.040 |
Why?
| | Boronic Acids | 12 | 2013 | 180 | 1.030 |
Why?
| | Pyrazines | 12 | 2013 | 188 | 1.020 |
Why?
| | Bone Marrow | 18 | 2024 | 359 | 0.980 |
Why?
| | Plasma Cells | 12 | 2025 | 234 | 0.970 |
Why?
| | Proteasome Inhibitors | 5 | 2024 | 104 | 0.960 |
Why?
| | Immunotherapy | 6 | 2024 | 266 | 0.910 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 75 | 0.910 |
Why?
| | Disease-Free Survival | 24 | 2019 | 466 | 0.870 |
Why?
| | Dexamethasone | 14 | 2024 | 429 | 0.840 |
Why?
| | B-Lymphocytes | 5 | 2024 | 178 | 0.840 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2014 | 67 | 0.810 |
Why?
| | Melphalan | 9 | 2020 | 180 | 0.810 |
Why?
| | Cancer Vaccines | 3 | 2010 | 79 | 0.800 |
Why?
| | Follow-Up Studies | 26 | 2024 | 2318 | 0.790 |
Why?
| | Hyperhidrosis | 1 | 2022 | 2 | 0.760 |
Why?
| | Sweat | 1 | 2022 | 9 | 0.750 |
Why?
| | Survival Rate | 24 | 2020 | 949 | 0.740 |
Why?
| | Lymphoma, B-Cell | 3 | 2022 | 60 | 0.730 |
Why?
| | Drug Approval | 1 | 2022 | 41 | 0.730 |
Why?
| | Aged, 80 and over | 24 | 2026 | 3494 | 0.710 |
Why?
| | Positron-Emission Tomography | 8 | 2025 | 298 | 0.700 |
Why?
| | Patient Participation | 1 | 2022 | 72 | 0.690 |
Why?
| | Ehrlichia chaffeensis | 1 | 2021 | 5 | 0.690 |
Why?
| | T-Lymphocytes | 8 | 2024 | 321 | 0.690 |
Why?
| | Cryosurgery | 1 | 2021 | 36 | 0.680 |
Why?
| | Ehrlichiosis | 1 | 2021 | 15 | 0.680 |
Why?
| | Immunoglobulin Light Chains | 3 | 2017 | 90 | 0.670 |
Why?
| | Disease Progression | 17 | 2025 | 880 | 0.670 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 31 | 0.660 |
Why?
| | Embolization, Therapeutic | 1 | 2021 | 91 | 0.650 |
Why?
| | Cell Proliferation | 10 | 2023 | 1031 | 0.630 |
Why?
| | Neoplasm, Residual | 9 | 2025 | 171 | 0.620 |
Why?
| | Chromosomal Instability | 1 | 2019 | 16 | 0.610 |
Why?
| | Neoplasms, Plasma Cell | 3 | 2024 | 35 | 0.600 |
Why?
| | Membrane Proteins | 3 | 2006 | 333 | 0.600 |
Why?
| | Survival Analysis | 18 | 2024 | 659 | 0.590 |
Why?
| | Adrenal Cortex Hormones | 2 | 2023 | 116 | 0.580 |
Why?
| | Immunologic Factors | 2 | 2018 | 117 | 0.580 |
Why?
| | Chromosome Aberrations | 12 | 2023 | 297 | 0.560 |
Why?
| | Epigenesis, Genetic | 4 | 2023 | 412 | 0.560 |
Why?
| | Dendritic Cells | 3 | 2014 | 133 | 0.550 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 274 | 0.550 |
Why?
| | POEMS Syndrome | 1 | 2018 | 34 | 0.550 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 197 | 0.540 |
Why?
| | Thyroid Neoplasms | 1 | 2019 | 113 | 0.540 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2024 | 505 | 0.530 |
Why?
| | Prealbumin | 2 | 2014 | 22 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2023 | 238 | 0.510 |
Why?
| | Receptors, Interleukin-6 | 2 | 2014 | 22 | 0.500 |
Why?
| | Cardiomyopathies | 2 | 2014 | 120 | 0.470 |
Why?
| | Mutation | 10 | 2022 | 1337 | 0.470 |
Why?
| | Risk Assessment | 11 | 2025 | 1368 | 0.450 |
Why?
| | Risk Factors | 21 | 2026 | 4017 | 0.450 |
Why?
| | Osteolysis | 4 | 2022 | 74 | 0.440 |
Why?
| | Immunotoxins | 1 | 2014 | 6 | 0.430 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2012 | 55 | 0.420 |
Why?
| | Recurrence | 13 | 2024 | 694 | 0.420 |
Why?
| | Clonal Evolution | 3 | 2020 | 59 | 0.410 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2024 | 350 | 0.410 |
Why?
| | Practice Guidelines as Topic | 4 | 2023 | 502 | 0.410 |
Why?
| | Hematopoietic Stem Cells | 3 | 2026 | 189 | 0.400 |
Why?
| | Health Status | 1 | 2015 | 306 | 0.390 |
Why?
| | Cyclophosphamide | 5 | 2021 | 178 | 0.390 |
Why?
| | Amyloidosis | 1 | 2014 | 83 | 0.390 |
Why?
| | Transplantation, Homologous | 5 | 2017 | 154 | 0.390 |
Why?
| | Thrombocytopenia | 3 | 2025 | 89 | 0.390 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2025 | 133 | 0.380 |
Why?
| | Fluorodeoxyglucose F18 | 6 | 2021 | 182 | 0.380 |
Why?
| | Remission Induction | 13 | 2021 | 221 | 0.370 |
Why?
| | Neutropenia | 2 | 2023 | 113 | 0.370 |
Why?
| | Genome-Wide Association Study | 3 | 2024 | 184 | 0.370 |
Why?
| | Receptors, KIR | 2 | 2008 | 11 | 0.360 |
Why?
| | Bone Diseases | 3 | 2021 | 94 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 3 | 2024 | 533 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2020 | 1367 | 0.350 |
Why?
| | Prospective Studies | 9 | 2025 | 2411 | 0.350 |
Why?
| | Pyrimidines | 2 | 2022 | 205 | 0.340 |
Why?
| | Cytokines | 3 | 2025 | 627 | 0.340 |
Why?
| | Lymph Nodes | 5 | 2025 | 252 | 0.340 |
Why?
| | Azacitidine | 1 | 2010 | 39 | 0.330 |
Why?
| | Benzamides | 1 | 2010 | 52 | 0.330 |
Why?
| | Evolution, Molecular | 2 | 2021 | 97 | 0.330 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 60 | 0.330 |
Why?
| | C-Reactive Protein | 6 | 2022 | 152 | 0.320 |
Why?
| | Prednisone | 2 | 2021 | 101 | 0.320 |
Why?
| | Doxorubicin | 6 | 2021 | 247 | 0.310 |
Why?
| | Drug Administration Schedule | 5 | 2015 | 370 | 0.300 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2020 | 83 | 0.300 |
Why?
| | Chromosome Deletion | 5 | 2023 | 138 | 0.300 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2026 | 266 | 0.300 |
Why?
| | Pelvis | 2 | 2021 | 66 | 0.300 |
Why?
| | Metaphase | 4 | 2016 | 47 | 0.300 |
Why?
| | Quality of Life | 1 | 2015 | 902 | 0.290 |
Why?
| | Vaccination | 4 | 2022 | 310 | 0.290 |
Why?
| | Membrane Glycoproteins | 2 | 2009 | 238 | 0.290 |
Why?
| | Paraproteinemias | 3 | 2022 | 72 | 0.290 |
Why?
| | Disease Management | 3 | 2025 | 187 | 0.280 |
Why?
| | Animals | 15 | 2024 | 13526 | 0.280 |
Why?
| | Proportional Hazards Models | 7 | 2024 | 445 | 0.280 |
Why?
| | Placebo Effect | 2 | 2020 | 16 | 0.280 |
Why?
| | Bone Neoplasms | 4 | 2013 | 188 | 0.280 |
Why?
| | Fever | 3 | 2025 | 112 | 0.270 |
Why?
| | Adoptive Transfer | 1 | 2007 | 29 | 0.270 |
Why?
| | Young Adult | 8 | 2025 | 4511 | 0.270 |
Why?
| | Retrospective Studies | 14 | 2026 | 6819 | 0.270 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 47 | 0.270 |
Why?
| | Chromatin | 3 | 2023 | 145 | 0.260 |
Why?
| | Cytogenetic Analysis | 5 | 2023 | 79 | 0.260 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 145 | 0.260 |
Why?
| | DNA Methylation | 4 | 2023 | 592 | 0.260 |
Why?
| | Boron Compounds | 2 | 2024 | 20 | 0.250 |
Why?
| | Registries | 4 | 2025 | 652 | 0.250 |
Why?
| | Chromans | 2 | 2024 | 34 | 0.250 |
Why?
| | Vincristine | 3 | 2021 | 89 | 0.250 |
Why?
| | Cell Membrane | 1 | 2007 | 233 | 0.250 |
Why?
| | Mice, SCID | 6 | 2013 | 180 | 0.250 |
Why?
| | Angiogenesis Inhibitors | 5 | 2010 | 186 | 0.250 |
Why?
| | Glycine | 2 | 2024 | 75 | 0.250 |
Why?
| | Down-Regulation | 1 | 2007 | 344 | 0.250 |
Why?
| | Neoplasm Staging | 6 | 2024 | 774 | 0.240 |
Why?
| | Antigens, CD34 | 1 | 2026 | 76 | 0.240 |
Why?
| | Cytomegalovirus | 1 | 2026 | 42 | 0.240 |
Why?
| | Consensus | 3 | 2025 | 206 | 0.240 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 1470 | 0.230 |
Why?
| | Vitamin E | 2 | 2024 | 76 | 0.230 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2017 | 35 | 0.230 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 49 | 0.230 |
Why?
| | Virus Activation | 1 | 2026 | 49 | 0.230 |
Why?
| | Transplantation Conditioning | 5 | 2008 | 96 | 0.230 |
Why?
| | Mice | 11 | 2024 | 5982 | 0.230 |
Why?
| | Case-Control Studies | 6 | 2024 | 1212 | 0.230 |
Why?
| | Bone Resorption | 2 | 2022 | 304 | 0.230 |
Why?
| | Infusions, Intravenous | 3 | 2015 | 211 | 0.230 |
Why?
| | Flow Cytometry | 4 | 2012 | 400 | 0.230 |
Why?
| | Connective Tissue Diseases | 1 | 2025 | 20 | 0.220 |
Why?
| | Antibody Formation | 1 | 2005 | 49 | 0.220 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2025 | 64 | 0.220 |
Why?
| | Time Factors | 11 | 2021 | 2991 | 0.210 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.210 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1038 | 0.210 |
Why?
| | Autoantibodies | 1 | 2025 | 120 | 0.210 |
Why?
| | Monocytes | 2 | 2020 | 126 | 0.210 |
Why?
| | Gene Expression | 2 | 2018 | 618 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2022 | 180 | 0.200 |
Why?
| | Cell Cycle Proteins | 2 | 2022 | 170 | 0.200 |
Why?
| | Blotting, Western | 3 | 2015 | 587 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2020 | 32 | 0.200 |
Why?
| | Radiation-Protective Agents | 1 | 2024 | 69 | 0.200 |
Why?
| | Signal Transduction | 6 | 2021 | 1748 | 0.200 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2011 | 141 | 0.200 |
Why?
| | Integrin beta Chains | 1 | 2023 | 14 | 0.200 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2026 | 63 | 0.200 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 140 | 0.200 |
Why?
| | Integrins | 1 | 2023 | 34 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2015 | 729 | 0.190 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1723 | 0.190 |
Why?
| | Sweating | 1 | 2022 | 13 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 78 | 0.190 |
Why?
| | Tumor Cells, Cultured | 4 | 2013 | 441 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 10 | 2016 | 487 | 0.180 |
Why?
| | Proteomics | 3 | 2021 | 336 | 0.180 |
Why?
| | DNA, Intergenic | 1 | 2022 | 6 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2022 | 37 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 52 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 228 | 0.180 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2022 | 38 | 0.180 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 93 | 0.180 |
Why?
| | United States | 4 | 2022 | 5409 | 0.180 |
Why?
| | Influenza, Human | 1 | 2022 | 88 | 0.180 |
Why?
| | Mediastinum | 1 | 2021 | 22 | 0.170 |
Why?
| | Chromosomes, Human, Pair 14 | 3 | 2020 | 76 | 0.170 |
Why?
| | Apoptosis | 5 | 2018 | 1139 | 0.170 |
Why?
| | Receptors, Glucocorticoid | 2 | 2012 | 34 | 0.170 |
Why?
| | Epigenomics | 1 | 2021 | 76 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2019 | 148 | 0.170 |
Why?
| | Axilla | 1 | 2021 | 92 | 0.170 |
Why?
| | Ubiquitination | 1 | 2021 | 58 | 0.170 |
Why?
| | Alleles | 3 | 2021 | 277 | 0.170 |
Why?
| | Multiple Organ Failure | 1 | 2021 | 51 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 110 | 0.170 |
Why?
| | Salvage Therapy | 6 | 2013 | 138 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-maf | 2 | 2020 | 19 | 0.170 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 1 | 0.170 |
Why?
| | Interferon-gamma | 3 | 2014 | 174 | 0.170 |
Why?
| | Adolescent | 7 | 2025 | 6907 | 0.160 |
Why?
| | Rare Diseases | 1 | 2020 | 47 | 0.160 |
Why?
| | Transcriptome | 5 | 2025 | 367 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.160 |
Why?
| | Radiopharmaceuticals | 4 | 2021 | 198 | 0.160 |
Why?
| | Cell Cycle | 1 | 2021 | 237 | 0.160 |
Why?
| | Longitudinal Studies | 5 | 2024 | 774 | 0.160 |
Why?
| | Interferon Type I | 1 | 2020 | 28 | 0.160 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.160 |
Why?
| | Myelodysplastic Syndromes | 2 | 2013 | 87 | 0.160 |
Why?
| | Multivariate Analysis | 8 | 2021 | 598 | 0.160 |
Why?
| | ROC Curve | 2 | 2025 | 246 | 0.160 |
Why?
| | Leukemia, Plasma Cell | 1 | 2020 | 35 | 0.160 |
Why?
| | Research Design | 2 | 2020 | 373 | 0.160 |
Why?
| | Genomics | 4 | 2023 | 271 | 0.160 |
Why?
| | DNA | 1 | 2023 | 535 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 58 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2015 | 975 | 0.150 |
Why?
| | Measles virus | 1 | 2019 | 8 | 0.150 |
Why?
| | Measles | 1 | 2019 | 7 | 0.150 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 112 | 0.150 |
Why?
| | Data Collection | 1 | 2020 | 288 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2022 | 221 | 0.150 |
Why?
| | Biopsy | 5 | 2018 | 600 | 0.150 |
Why?
| | Oncolytic Virotherapy | 1 | 2019 | 28 | 0.150 |
Why?
| | Patient Safety | 1 | 2020 | 103 | 0.150 |
Why?
| | Sirolimus | 1 | 2019 | 72 | 0.150 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 9 | 0.150 |
Why?
| | Cell Differentiation | 6 | 2022 | 681 | 0.140 |
Why?
| | Precancerous Conditions | 2 | 2010 | 87 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 275 | 0.140 |
Why?
| | Syndrome | 1 | 2019 | 248 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 171 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 312 | 0.140 |
Why?
| | Spleen | 1 | 2019 | 166 | 0.140 |
Why?
| | MafB Transcription Factor | 1 | 2018 | 9 | 0.140 |
Why?
| | Graft vs Host Disease | 4 | 2007 | 93 | 0.140 |
Why?
| | Genomic Instability | 2 | 2016 | 88 | 0.140 |
Why?
| | Immunomodulation | 1 | 2018 | 36 | 0.140 |
Why?
| | Phosphotransferases | 1 | 2018 | 18 | 0.140 |
Why?
| | Chemokines | 1 | 2018 | 78 | 0.140 |
Why?
| | Plasma | 1 | 2018 | 47 | 0.140 |
Why?
| | Osteoclasts | 3 | 2022 | 428 | 0.140 |
Why?
| | Myeloablative Agonists | 2 | 2008 | 32 | 0.140 |
Why?
| | Genes, Neoplasm | 2 | 2015 | 31 | 0.140 |
Why?
| | Models, Biological | 2 | 2018 | 737 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 131 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 5 | 2013 | 1583 | 0.130 |
Why?
| | Gene Dosage | 2 | 2015 | 76 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2018 | 76 | 0.130 |
Why?
| | Hexokinase | 1 | 2017 | 16 | 0.130 |
Why?
| | Communication | 1 | 2019 | 263 | 0.130 |
Why?
| | Heterozygote | 2 | 2014 | 89 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2018 | 87 | 0.130 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| | HLA-A Antigens | 2 | 2007 | 11 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 405 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 412 | 0.120 |
Why?
| | Gene Frequency | 2 | 2013 | 97 | 0.120 |
Why?
| | Syndecan-1 | 4 | 2021 | 73 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 180 | 0.120 |
Why?
| | Lymphocyte Activation | 2 | 2017 | 163 | 0.120 |
Why?
| | Critical Illness | 1 | 2018 | 316 | 0.120 |
Why?
| | Tumor Burden | 3 | 2020 | 132 | 0.120 |
Why?
| | Confidence Intervals | 2 | 2014 | 158 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2016 | 112 | 0.120 |
Why?
| | Erythrocyte Indices | 1 | 2015 | 7 | 0.120 |
Why?
| | Biomarkers, Pharmacological | 2 | 2012 | 26 | 0.120 |
Why?
| | DNA Copy Number Variations | 3 | 2022 | 117 | 0.120 |
Why?
| | Coculture Techniques | 2 | 2013 | 146 | 0.110 |
Why?
| | Hemoglobins | 2 | 2013 | 114 | 0.110 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.110 |
Why?
| | Hematologic Diseases | 1 | 2014 | 21 | 0.110 |
Why?
| | Half-Life | 1 | 2014 | 86 | 0.110 |
Why?
| | International Cooperation | 1 | 2014 | 52 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 233 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 127 | 0.110 |
Why?
| | Iron | 1 | 2015 | 130 | 0.110 |
Why?
| | Area Under Curve | 1 | 2014 | 185 | 0.110 |
Why?
| | Antibodies | 2 | 2024 | 147 | 0.100 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2013 | 5 | 0.100 |
Why?
| | Reference Values | 1 | 2014 | 311 | 0.100 |
Why?
| | Renal Insufficiency | 2 | 2021 | 108 | 0.100 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2008 | 78 | 0.100 |
Why?
| | Emotions | 1 | 2015 | 177 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2016 | 1517 | 0.100 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2014 | 42 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2014 | 1049 | 0.100 |
Why?
| | Inflammation Mediators | 1 | 2014 | 115 | 0.100 |
Why?
| | Administration, Metronomic | 1 | 2013 | 7 | 0.100 |
Why?
| | Cisplatin | 4 | 2013 | 282 | 0.100 |
Why?
| | Cystatin M | 2 | 2024 | 17 | 0.100 |
Why?
| | Macaca mulatta | 2 | 2024 | 94 | 0.100 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.100 |
Why?
| | Central Nervous System Neoplasms | 1 | 2013 | 69 | 0.100 |
Why?
| | beta Catenin | 1 | 2013 | 107 | 0.100 |
Why?
| | Oligopeptides | 1 | 2013 | 94 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2004 | 91 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.100 |
Why?
| | Edema | 2 | 2025 | 64 | 0.100 |
Why?
| | Leukemia | 1 | 2013 | 67 | 0.100 |
Why?
| | Myelolipoma | 1 | 2012 | 9 | 0.090 |
Why?
| | Cell Survival | 2 | 2020 | 600 | 0.090 |
Why?
| | Pain | 1 | 2015 | 351 | 0.090 |
Why?
| | Mental Health | 1 | 2015 | 248 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2012 | 7 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 8 | 0.090 |
Why?
| | Clone Cells | 2 | 2023 | 76 | 0.090 |
Why?
| | Maintenance Chemotherapy | 1 | 2012 | 52 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 189 | 0.090 |
Why?
| | Models, Genetic | 2 | 2016 | 169 | 0.090 |
Why?
| | Interleukin-2 | 1 | 2012 | 69 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2024 | 202 | 0.090 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 90 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 134 | 0.090 |
Why?
| | Cell Movement | 1 | 2013 | 279 | 0.090 |
Why?
| | Hemangioma | 1 | 2013 | 86 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2012 | 62 | 0.090 |
Why?
| | Karyotype | 2 | 2026 | 22 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2025 | 192 | 0.090 |
Why?
| | Genotype | 1 | 2013 | 563 | 0.090 |
Why?
| | Arkansas | 5 | 2021 | 2068 | 0.090 |
Why?
| | Transcriptional Elongation Factors | 2 | 2022 | 17 | 0.090 |
Why?
| | Transduction, Genetic | 2 | 2014 | 44 | 0.090 |
Why?
| | Models, Statistical | 2 | 2014 | 229 | 0.080 |
Why?
| | Chemokine CXCL13 | 2 | 2022 | 6 | 0.080 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2008 | 59 | 0.080 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.080 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.080 |
Why?
| | CD40 Ligand | 1 | 2010 | 14 | 0.080 |
Why?
| | Hypersensitivity, Delayed | 1 | 2010 | 18 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2010 | 40 | 0.080 |
Why?
| | Up-Regulation | 4 | 2018 | 456 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2010 | 85 | 0.080 |
Why?
| | HIV Seropositivity | 1 | 2010 | 28 | 0.080 |
Why?
| | Immunity, Cellular | 1 | 2010 | 64 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 52 | 0.080 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2010 | 18 | 0.080 |
Why?
| | Cell Line | 2 | 2013 | 1016 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2013 | 1569 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2014 | 459 | 0.080 |
Why?
| | Etoposide | 2 | 2007 | 71 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 78 | 0.080 |
Why?
| | Placenta | 1 | 2011 | 146 | 0.080 |
Why?
| | Radiography | 4 | 2012 | 476 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 452 | 0.070 |
Why?
| | Histones | 2 | 2021 | 318 | 0.070 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2008 | 26 | 0.070 |
Why?
| | Hospitalization | 2 | 2024 | 749 | 0.070 |
Why?
| | Transcription Factors | 2 | 2023 | 571 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2012 | 346 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2008 | 14 | 0.070 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2008 | 15 | 0.070 |
Why?
| | Bone and Bones | 3 | 2021 | 501 | 0.070 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2008 | 64 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 90 | 0.070 |
Why?
| | Haplotypes | 1 | 2008 | 96 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 23 | 0.070 |
Why?
| | Gene Deletion | 1 | 2009 | 279 | 0.070 |
Why?
| | Ligands | 1 | 2008 | 203 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 36 | 0.070 |
Why?
| | Osteogenesis | 1 | 2011 | 374 | 0.070 |
Why?
| | Twins | 1 | 2007 | 21 | 0.070 |
Why?
| | Busulfan | 1 | 2007 | 18 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 92 | 0.070 |
Why?
| | Herpesviridae Infections | 2 | 2019 | 57 | 0.070 |
Why?
| | Immunophenotyping | 1 | 2007 | 118 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 122 | 0.070 |
Why?
| | Caspases | 2 | 2018 | 101 | 0.060 |
Why?
| | Antimetabolites | 1 | 2006 | 12 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2012 | 500 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 158 | 0.060 |
Why?
| | Blood Proteins | 1 | 2007 | 84 | 0.060 |
Why?
| | Antibodies, Neoplasm | 1 | 2006 | 27 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 253 | 0.060 |
Why?
| | Graft vs Leukemia Effect | 1 | 2006 | 2 | 0.060 |
Why?
| | Chromosome Banding | 1 | 2006 | 24 | 0.060 |
Why?
| | Plasmacytoma | 1 | 2006 | 45 | 0.060 |
Why?
| | Cohort Studies | 3 | 2020 | 1557 | 0.060 |
Why?
| | Bone Marrow Transplantation | 2 | 2022 | 110 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 145 | 0.060 |
Why?
| | MicroRNAs | 1 | 2010 | 397 | 0.060 |
Why?
| | Amiloride | 1 | 2005 | 7 | 0.060 |
Why?
| | HLA-A2 Antigen | 1 | 2005 | 11 | 0.060 |
Why?
| | Decision Trees | 1 | 2025 | 23 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 867 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 1180 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 934 | 0.060 |
Why?
| | Child | 3 | 2025 | 7379 | 0.060 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2016 | 30 | 0.060 |
Why?
| | Japan | 1 | 2025 | 42 | 0.060 |
Why?
| | Autoantigens | 1 | 2025 | 46 | 0.060 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 6 | 0.050 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 7 | 0.050 |
Why?
| | Phthalimides | 1 | 2024 | 2 | 0.050 |
Why?
| | Piperidones | 1 | 2024 | 6 | 0.050 |
Why?
| | Enoxaparin | 1 | 2004 | 32 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 38 | 0.050 |
Why?
| | Retreatment | 1 | 2024 | 60 | 0.050 |
Why?
| | NF-kappa B | 2 | 2018 | 327 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 64 | 0.050 |
Why?
| | Ferritins | 1 | 2024 | 38 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 121 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 80 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 58 | 0.050 |
Why?
| | Neoplasms | 1 | 2014 | 1334 | 0.050 |
Why?
| | Epidemiologic Methods | 3 | 2008 | 47 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 146 | 0.050 |
Why?
| | Gene Silencing | 2 | 2016 | 122 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 363 | 0.050 |
Why?
| | Cluster Analysis | 3 | 2010 | 237 | 0.050 |
Why?
| | Cell Communication | 1 | 2023 | 73 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Patients | 1 | 2022 | 52 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 32 | 0.050 |
Why?
| | Whole-Body Irradiation | 1 | 2022 | 129 | 0.050 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2022 | 18 | 0.050 |
Why?
| | Phenotype | 1 | 2025 | 803 | 0.050 |
Why?
| | Inheritance Patterns | 1 | 2022 | 22 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2022 | 62 | 0.040 |
Why?
| | Risk | 2 | 2014 | 306 | 0.040 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 36 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2022 | 53 | 0.040 |
Why?
| | Oncogenes | 1 | 2021 | 61 | 0.040 |
Why?
| | Patient Selection | 1 | 2023 | 273 | 0.040 |
Why?
| | Age of Onset | 2 | 2013 | 109 | 0.040 |
Why?
| | Phylogeny | 1 | 2022 | 231 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 280 | 0.040 |
Why?
| | RANK Ligand | 1 | 2022 | 188 | 0.040 |
Why?
| | Rabbits | 2 | 2013 | 372 | 0.040 |
Why?
| | Child, Preschool | 2 | 2020 | 4162 | 0.040 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2022 | 181 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 128 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 620 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 149 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| | Fibrosis | 1 | 2021 | 198 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 11 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 17 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 59 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 32 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 56 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 233 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 72 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 561 | 0.040 |
Why?
| | Genetic Loci | 1 | 2020 | 48 | 0.040 |
Why?
| | False Negative Reactions | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 179 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 223 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 281 | 0.040 |
Why?
| | Incidence | 2 | 2013 | 1085 | 0.040 |
Why?
| | Europe | 1 | 2019 | 91 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 44 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2019 | 37 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 209 | 0.040 |
Why?
| | Genome, Viral | 1 | 2019 | 78 | 0.040 |
Why?
| | beta 2-Microglobulin | 2 | 2009 | 39 | 0.040 |
Why?
| | DNA, Viral | 1 | 2019 | 136 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 1133 | 0.040 |
Why?
| | Virus Diseases | 1 | 2019 | 47 | 0.040 |
Why?
| | Fibrinogen | 1 | 2018 | 33 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2018 | 46 | 0.040 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2018 | 21 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.040 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 188 | 0.040 |
Why?
| | Platelet Count | 2 | 2008 | 68 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.030 |
Why?
| | Pathology, Molecular | 1 | 2018 | 28 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 62 | 0.030 |
Why?
| | Data Interpretation, Statistical | 2 | 2010 | 169 | 0.030 |
Why?
| | Databases, Factual | 2 | 2013 | 742 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 55 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2017 | 66 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 128 | 0.030 |
Why?
| | Lamins | 1 | 2016 | 5 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 187 | 0.030 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2016 | 18 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 563 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 46 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 92 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 89 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 267 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 105 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2006 | 145 | 0.030 |
Why?
| | Glycolysis | 1 | 2016 | 76 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 1034 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 98 | 0.030 |
Why?
| | Phosphorylation | 1 | 2016 | 533 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 230 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 38 | 0.030 |
Why?
| | Gene Fusion | 1 | 2014 | 9 | 0.030 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2014 | 7 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 471 | 0.030 |
Why?
| | Capsid | 1 | 2014 | 2 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 6 | 0.030 |
Why?
| | HIV-1 | 1 | 2014 | 60 | 0.030 |
Why?
| | Homozygote | 1 | 2013 | 57 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 29 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2014 | 127 | 0.020 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2013 | 4 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2013 | 30 | 0.020 |
Why?
| | Acrylamides | 1 | 2013 | 12 | 0.020 |
Why?
| | Dependovirus | 1 | 2014 | 104 | 0.020 |
Why?
| | Niacinamide | 1 | 2013 | 24 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2013 | 75 | 0.020 |
Why?
| | Amides | 1 | 2013 | 36 | 0.020 |
Why?
| | NAD | 1 | 2013 | 45 | 0.020 |
Why?
| | Sirtuin 1 | 1 | 2013 | 29 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 55 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 35 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 109 | 0.020 |
Why?
| | Transplantation Chimera | 2 | 2003 | 16 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 214 | 0.020 |
Why?
| | Piperidines | 1 | 2013 | 98 | 0.020 |
Why?
| | Infant | 1 | 2020 | 3805 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2011 | 20 | 0.020 |
Why?
| | Induction Chemotherapy | 1 | 2012 | 65 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 393 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2011 | 20 | 0.020 |
Why?
| | HIV Infections | 1 | 2016 | 402 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2011 | 78 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 747 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2011 | 52 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 371 | 0.020 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2010 | 24 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2010 | 48 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2010 | 48 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 69 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2010 | 70 | 0.020 |
Why?
| | Argonaute Proteins | 1 | 2010 | 12 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 133 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2010 | 77 | 0.020 |
Why?
| | Polyploidy | 1 | 2009 | 9 | 0.020 |
Why?
| | Bone Marrow Examination | 1 | 2009 | 11 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2009 | 57 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 237 | 0.020 |
Why?
| | Ploidies | 1 | 2008 | 10 | 0.020 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2008 | 37 | 0.020 |
Why?
| | Serum Albumin | 1 | 2008 | 56 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 95 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 228 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 630 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 175 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2008 | 489 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2007 | 56 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 50 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| | Syndecans | 1 | 2006 | 37 | 0.020 |
Why?
| | Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 45 | 0.020 |
Why?
| | Proteoglycans | 1 | 2006 | 86 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 208 | 0.010 |
Why?
| | Brain | 1 | 2013 | 1350 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 120 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 2608 | 0.010 |
Why?
| | Probability | 1 | 2003 | 171 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| | Administration, Oral | 1 | 2003 | 456 | 0.010 |
Why?
| | Tissue Donors | 1 | 2003 | 130 | 0.010 |
Why?
|
|
Van Rhee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|